Torsadogenic risk of antipsychotics: Combining adverse event reports with drug utilization data across Europe

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Raschi, Emanuel ^a   Poluzzi, Elisabetta ^a   Godman, Brian ^b,c   Koci, Ariola ^a   Moretti, Ugo ^d   Kalaba, Marija ^e   Bennie, Marion ^c,f   Barbui, Corrado ^d   Wettermark, Bjorn ^b,g   Sturkenboom, Miriam ^h   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d UNIVERSITY OF VERONA   (Italy)

^e Republic Institute for Health Insurance   (Serbia)

^f INFORMATION SERVICES DIVISION   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; CYAMEMAZINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANALYTICAL PARAMETERS; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DATA ANALYSIS; DRUG CONTROL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG UTILIZATION; ESTONIA; EUROPE; FOOD AND DRUG ADMINISTRATION; FRANCE; GEOGRAPHIC DISTRIBUTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFORMATION PROCESSING; NORWAY; POPULATION EXPOSURE; POPULATION RESEARCH; POPULATION RISK; REPORTING ODDS RATIO; RISK ASSESSMENT; SERBIA; SLOVENIA; SUDDEN CARDIAC DEATH; TORSADE DES POINTES; TREND STUDY; CHEMICALLY INDUCED; RISK; TORSADES DE POINTES; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; DRUG UTILIZATION; EUROPE; HUMANS; PHARMACOVIGILANCE; RISK; TORSADES DE POINTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84894256313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081208     Document Type: Article

References (57)

1. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17: 1206-1227. doi:10.1038/mp.2012.47. PubMed: 22584864.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223. doi:10.1056/NEJMoa051688. PubMed: 16172203. (Pubitemid 41345943)
3. Leucht S, Corves C, Arbter D, Engel RR, Li C et al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41. doi:10.1016/S0140-6736(08)61764-X. PubMed: 19058842.
4. Hartling L, bou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D et al. (2012) Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med 157: 498-511
5. NICE (National Institute for Health and Clinical Excellence) (2009) Schizophrenia - Core interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. Nice Clinical Guideline No.82. 14 March: 2013.
6. Godman B, Bucsics A, Burkhardt T, Piessnegger J, Schmitzer M et al. (2012) Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future. Front. Pharmacol 3: 198.
7. Bennie M, Bishop I, Godman B, Barbui C, Raschi E et al. (2013) Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. Int J Clin Pract 67: 170-180. doi:10.1111/ijcp.12100. PubMed: 23305478.
8. Verdoux H, Tournier M, Bégaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121: 4-10. doi:10.1111/j.1600-0447.2009.01425.x. PubMed: 20059452.
9. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (2011) Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 20: 177-184. doi:10.1002/pds.2082. PubMed: 21254289.
10. Hauben M, Bate A (2009) Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today 14: 343-357. doi:10.1016/j.drudis.2008.12.012. PubMed: 19187799.
11. Cha DS, McIntyre RS (2012) Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother 13: 1587-1598. doi:10.1517/14656566.2012.656590. PubMed: 22304541.
12. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F et al. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123: 225-233. doi:10.1016/j.schres.2010.07.012. PubMed: 20692814.
13. Titier K, Girodet PO, Verdoux H, Molimard M, Bégaud B et al. (2005) Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf 28: 35-51. doi:10.2165/00002018-200528010-00003. PubMed: 15649104.
14. Haddad PM, Sharma SG (2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21: 911-936. doi:10.2165/00023210-200721110-00004. PubMed: 17927296. (Pubitemid 47557106)
15. Poluzzi E, Raschi E, Moretti U, De Ponti F (2009) Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 18: 512-518. doi:10.1002/pds.1746. PubMed: 19358226.
16. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ (2010) The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med 5: E8-16. doi:10.1002/jhm.669. PubMed: 20394022.
17. Meyer-Massetti C, Vaerini S, Rätz Bravo AE, Meier CR, Guglielmo BJ (2011) Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharm 33: 806-814. doi:10.1007/s11096-011-9541-y. PubMed: 21809143.
18. Jolly K, Gammage MD, Cheng KK, Bradburn P, Banting MV et al. (2009) Sudden death in patients receiving drugs tending to prolong the QT interval. Br J Clin Pharmacol 68: 743-751. doi:10.1111/j.1365-2125.2009.03496.x. PubMed: 19916999.
19. Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225-235. doi:10.1056/NEJMoa0806994. PubMed: 19144938.
20. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM (2008) Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 179: 438-446. doi:10.1503/cmaj.071540. PubMed: 18725616.
21. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC (2010) Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 170: 96-103. doi:10.1001/archinternmed.2009.456. PubMed: 20065205.
22. Comer JS, Mojtabai R, Olfson M (2011) National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatry 168: 1057-1065. doi:10.1176/appi.ajp.2011.11010087. PubMed: 21799067.
23. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C et al. (2011) Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 68: 190-197. doi:10.1001/archgenpsychiatry.2010.200. PubMed: 21300946.
24. Hoffman KB, Kraus C, Dimbil M, Golomb BA (2012) A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLOS ONE 7: e42866-. doi:10.1371/journal.pone.0042866. PubMed: 22936996.
25. Poluzzi E, Raschi E, Piccinni C, De Ponti F (2012) Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). In: A Karahoca. Data Mining Applications in Engineering and Medicine. Croatia. pp. 267-301.
26. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F (2010) Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting. System - Drug Saf 33: 303-314. doi:10.2165/11531850-000000000-00000.
27. Poluzzi E, Raschi E, Koci A, Moretti U, Spina E et al. (2013) Antipsychotics and torsadogenic risk: signals emerging from the FDA Adverse Event Reporting System database. Drug Saf 36: 467-479. doi:10.1007/s40264-013- 0032-z. PubMed: 23553446.
28. Hochberg AM, Hauben M (2009) Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria. Clin Pharmacol Ther 85: 600-606. doi:10.1038/clpt.2009.26. PubMed: 19322165.
29. Raschi E, Poluzzi E, Koci A, Moretti U, Sturkenboom M et al. (2013) Macrolides and torsadogenic risk: emerging issues from the FDA pharmacovigilance database. J Pharmacovigilance 1: 104.
30. Roden DM (1998) Taking the "idio" out of " idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 21: 1029-1034. doi:10.1111/j.1540-8159.1998.tb00148.x. PubMed: 9604234.
31. Wettermark B, Vlahovic-Palcevski V, Salvesen Blix H, Rønning M, Vander Stichele RH (2008) Pharmacoepidemiology and Therapeutic Risk Assessment. In: Hartzema, AG; Tilson HH, Chan KA Drug Utilization Research. Cincinnati. 159-195.
32. Nosè M, Tansella M, Thornicroft G, Schene A, Becker T et al. (2008) Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol 23: 287-290. doi:10.1097/YIC.0b013e328303ac75. PubMed: 18703938.
33. WHO (World Health Organization) (2003) Introduction to Drug Utilization Research. 14 March 2013.
34. Aagaard L, Strandell J, Melskens L, Petersen PS, Holme HE (2012) Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf 35: 1171-1182. doi:10.1007/BF03262002. PubMed: 23072620.
35. Srba J, Descikova V, Vlcek J (2012) Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009. Eur J Clin Pharmacol 68: 1057-1063. doi:10.1007/s00228-012-1219-4. PubMed: 22294060.
36. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D et al. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382: 951-962. doi:10.1016/S0140-6736(13)60733-3. PubMed: 23810019.
37. Wladysiuk M, Araszkiewicz A, Godman B, Szabert K, Barbui C et al. (2011) Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available. Appl Health Econ Health Policy 9: 101-110. doi:10.2165/11318840-000000000-00000. PubMed: 21271749.
38. Kalaba M, Godman B, Vuksanovic A, Bennie M, Malmström R (2012) Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? Journal Comparative Effectiveness Research 1: 539-549. doi:10.2217/cer.12.62.
39. Divac N, Tosevski DL, Babić D, Djurić D, Prostran M et al. (2006) Trends in consumption of psychiatric drugs in Serbia and Montenegro 2000-2004. Pharmacoepidemiol Drug Saf 15: 835-838. doi:10.1002/pds.1316. PubMed: 16958148. (Pubitemid 44762715)
40. Ravera S, Hummel SA, Stolk P, Heerdink RE, de Jong-van den Berg LT et al. (2009) The use of driving impairing medicines: a European survey. Eur J Clin Pharmacol 65: 1139-1147. doi:10.1007/s00228-009-0695-7. PubMed: 19621220.
41. Fürst J, Kocmur M (2003) Use of psychiatric drugs in Slovenia in comparison to Scandinavian countries. Pharmacoepidemiol Drug Saf 12: 399-403. doi:10.1002/pds.826. PubMed: 12899115. (Pubitemid 36903376)
42. Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H et al. (2009) Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. Br J Clin Pharmacol 67: 88-98. doi:10.1111/j.1365-2125.2008.03319.x. PubMed: 19076158.
43. Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW et al. (2013) Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis. PloS Med 10: e1001407-
44. Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lépine JP et al. (2000) Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 49: 80-86. PubMed: 10606841. (Pubitemid 30050490)
45. Bret MC, Bret P, Pariente A, Fourier-Réglat A (2007) The use of atypical antipsychotics in French psychiatric hospitals. Pharm World Sci 29: 551-556. doi:10.1007/s11096-007-9107-1. PubMed: 17638111. (Pubitemid 47389415)
46. Diatta T, Blazejewski S, Portier A, Lignot S, Quesnot A et al. (2007) Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a cross-sectional national survey. Fundam Clin Pharmacol 21: 371-378. doi:10.1111/j.1472-8206.2007.00492.x. PubMed: 17635175. (Pubitemid 47084024)
47. Mann E, Köpke S, Haastert B, Pitkälä K, Meyer G (2009) Psychotropic medication use among nursing home residents in Austria: a cross-sectional study. BMC Geriatr 9: 18. doi:10.1186/1471-2318-9-18. PubMed: 19460135.
48. Goossens H, Ferech M, Vander SR, Elseviers M (2005) Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365: 579-587. doi:10.1016/S0140-6736(05)70799-6. PubMed: 15708101. (Pubitemid 40247914)
49. Anderson N, Borlak J (2011) Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. PLOS ONE 6: e25221. doi:10.1371/journal.pone.0025221. PubMed: 22022383.
50. Muzyk AJ, Rayfield A, Revollo JY, Heinz H, Gagliardi JP (2012) Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Drug Saf 35: 547-553. doi:10.2165/11599960- 000000000-00000. PubMed: 22702639.
51. Muzyk AJ, Rivelli SK, Jiang W, Heinz H, Rayfield A et al. (2012) A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients. Drug Saf 35: 725-731. doi:10.2165/11631460-000000000-00000. PubMed: 22876752.
52. Richter T, Meyer G, Möhler R, Köpke S (2012) Psychosocial interventions for reducing antipsychotic medication in care home residents. Cochrane Database Syst Rev 12: CD008634: CD008634 PubMed: 23235663.
53. Stephenson CP, Karanges E, McGregor IS (2013) Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust N Z J Psychiatry 47: 74-87. doi:10.1177/0004867412466595. PubMed: 23144164.
54. Stephenson WP, Hauben M (2007) Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 16: 359-365. doi:10.1002/pds.1323. PubMed: 17019675. (Pubitemid 46656857)
55. Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18: 427-436. doi:10.1002/pds.1742. PubMed: 19358225.
56. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F (2013) The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 50: 569-577. doi:10.1007/s00592-011-0340-7. PubMed: 22008948.
57. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB et al. (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106: 86-94. doi:10.1111/j.1742-7843.2009.00494.x. PubMed: 19961477.